Christopher Gibson sold $3.3M of RXRX
Chief Executive Officer at RECURSION PHARMACEUTICALS, INC.. 618,175 shares at an average of $5.28, traded Aug 11, 2025, filed Aug 13, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.3M at market
- +10Share of holdings soldSold 41% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001601830-25-000130, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | CConversion Class A Common Stock10b5-1 | +423,666 | $0.00 | $0 | 1,504,919 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -500,300 | $5.28 | $2.6M | 1,004,619 | Aug 13, 2025 |
| Aug 11, 2025 | GGift Class A Common Stock10b5-1 | -10,000 | $0.00 | $0 | 994,619 | Aug 13, 2025 |
| Aug 11, 2025 | CConversion Class A Common Stockindirect: by LAHWRAN-3 LLC10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Class A Common Stockindirect: by LAHWRAN-3 LLC10b5-1 | -100,000 | $5.28 | $528k | 0 | Aug 13, 2025 |
| Aug 11, 2025 | CConversion Class A Common Stockindirect: by Gibson Family Trust10b5-1 | +17,875 | $0.00 | $0 | 17,875 | Aug 13, 2025 |
| Aug 11, 2025 | SOpen-market sale Class A Common Stockindirect: by Gibson Family Trust10b5-1 | -17,875 | $5.28 | $94k | 0 | Aug 13, 2025 |
| Aug 11, 2025 | CConversion Class B Common Stockderivative10b5-1 | -423,666 | $0.00 | $0 | 5,473,034 | Aug 13, 2025 |
| Aug 11, 2025 | CConversion Class B Common Stockderivativeindirect: by LAHWRAN-3 LLC10b5-1 | -100,000 | $0.00 | $0 | 386,000 | Aug 13, 2025 |
| Aug 11, 2025 | CConversion Class B Common Stockderivativeindirect: by Gibson Family Trust10b5-1 | -17,875 | $0.00 | $0 | 50,000 | Aug 13, 2025 |
Related signals
Other insiders at RECURSION PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $242k 50,000 shares | -1% | |
| 3Weak | RECURSION PHARMACEUTICALS, INC. | Robert Hershberg director | $125k 25,000 shares | -13% | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $79k 22,408 shares | -1% | |
| 13Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $100k 30,000 shares | -0% | |
| 0Weak | RECURSION PHARMACEUTICALS, INC. | Namandje Bumpus director | $13k 3,963 shares | -3% | |
| 13Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $110k 30,000 shares | -0% | |
| 3Weak | RECURSION PHARMACEUTICALS, INC. | Namandje Bumpus director | $16k 4,386 shares | -9% | |
| 5Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $106k 30,000 shares | -0% | |
| 5Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $93k 30,000 shares | -0% | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $130k 40,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.